WiseTech Global Stock And 2 Cash Flow Plays Worth A Closer Look

Central banks are weighing how hard to lean against persistent inflation, which keeps the path for interest rates uncertain and volatility in play. That kind of backdrop can leave solid cash generators mispriced as investors focus on headline risk. The Undervalued Stocks Based On Cash Flows screener looks for those gaps between price and cash flow potential. This article walks through three stocks that currently fit that bill.

The stocks covered below are just a sample, and the full screen surfaced 43 more companies with similarly compelling cash flow stories that are not included here. To identify and analyze the ideas that best match your style, head straight to the Undervalued Stocks Based On Cash Flows screener.

Mesoblast (ASX:MSB)

Mesoblast is a Melbourne based regenerative medicine company developing mesenchymal cell therapies for severe inflammatory and cardiovascular conditions, with its late stage Remestemcel L program the key link to the cash flow focused screener theme. The business currently earns about US$65 million from developing its cell technology platform for commercialization, while its A$3.3b market cap reflects investor expectations around how those therapies might translate into future revenue and cash generation.

Mesoblast could appeal if you are looking for a pure play on late stage cell therapies where future cash flows are the real story. Remestemcel L and Ryoncil sit at the center of that, with Phase III programs in chronic low back pain and heart failure and an FDA approved product in pediatric steroid refractory graft versus host disease already generating revenue. The opportunity is that SWS analysis sees the stock trading well below its DCF based fair value, even as recent trial milestones and expanding reimbursement add more data around the potential scale of those cash flows. The risk is that the company is still loss making, relies on external funding and needs multiple regulatory and commercial wins to support that valuation, which makes outcome timing and execution critical.

Mesoblast’s late stage pipeline, cash flow potential and current pricing look out of sync. Get the DCF valuation analysis for Mesoblast to see how those assumptions stack up and where the real swing factor may lie.

Build your own late stage cash flow watchlist

Mesoblast and the two other stocks in this list came from a single screen, but the real edge is in setting filters that reflect how you think about risk, value and future cash generation. Use our flexible Screener to combine valuation, growth, balance sheet and risk filters, or start with any of our curated Investing Ideas for ready made shortlists.

Lynas Rare Earths (ASX:LYC)

Lynas Rare Earths runs the Mt Weld mine in Western Australia and processing plants in Kalgoorlie and Malaysia, turning rare earth ore into higher value oxides used in permanent magnets and advanced electronics. All of its A$715.89 million in reported revenue comes from these Rare Earth Operations, which are the direct engine for the company’s cash flow story in this screener. With a market cap of about A$16.3 billion, Lynas Rare Earths is a large, specialised rare earth producer with integrated mining and processing.

For investors watching cash flow and valuation, Lynas Rare Earths is worth attention because the same Mt Weld to Gebeng chain that underpins its revenue is also the reason SWS’s DCF model sees the stock trading below estimated fair value. The company benefits from demand for rare earths in electrification and from policy support for non Chinese supply, yet still faces real risks around funding needs, regulatory pressure in Malaysia and reliance on a narrow set of products. Upcoming results in July and August 2026 will provide additional information on whether margins and cash generation are tracking closely enough to that cash flow focused thesis to justify closing any valuation gap.

Lynas Rare Earths has a revenue engine that does not fully line up with where the stock is priced. Get the full story with the DCF valuation analysis for Lynas Rare Earths and see what the market might be missing.

WiseTech Global (ASX:WTC)

WiseTech Global develops cloud based software that helps logistics providers manage the movement and storage of goods, with its CargoWise platform generating recurring subscription and services revenue that anchors the company’s cash flow profile under this screener theme. The company operates across the Americas, Asia Pacific and Europe, the Middle East and Africa, and has a market cap of about A$14.4b.

WiseTech Global is worth a closer look if you want exposure to global supply chain software where recurring cash flows are the main story rather than hardware or one off projects. CargoWise’s subscription model supports high margin, repeatable revenue and helps explain why SWS’s DCF work sees the stock trading below estimated fair value, even after a year in which net profit margins dropped and earnings declined. The recent ACCC investigation into competition issues and the integration of E2open both add real execution and regulatory risk. They also frame the key question: if WiseTech can convert its larger platform and AI enabled products into cleaner, growing free cash flow, today’s volatility could be setting up the next leg of the cash flow story.

WiseTech Global’s cash flow story may be getting lost behind short term earnings noise and ACCC headlines. Yet the real inflection point could be in the projections buried inside the analyst forecasts for WiseTech Global

Seeking Fresh Alternatives Before Others Do

Markets move fast and the next breakout stories rarely stay under the radar for long. Spot fresh momentum and cash flow stories while it matters. Get in early.

• Track companies already building momentum in artificial intelligence before the crowd catches up by scouting the 54 AI infrastructure stocks that are wiring the next wave of compute growth.
• Target resilient income ideas that aim to keep paying even when conditions change by scanning the curated 6 dividend fortresses built around stronger balance sheets and richer yields.
• Hunt for early stage growth stories with real businesses behind them by checking the curated 56 elite penny stocks with strong financials that pair smaller market caps with healthier financial profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com